Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Support for per-se laws was higher among those in states that legalized recreational marijuana and in states with per-se laws. Materials and methods. Study sample. never vs. at least once). (2)

Policy 59

Policy Safety Marijuana Data 59

TheAnswerPage

JANUARY 11, 2022

We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 24, 2019

Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding. Tools and resources. Chronic pain.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. launched their app platform Mindleap 2.0

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

CannaMD

MARCH 8, 2021

Download CannaMD ‘s official opposition memo , outlining court precedents, research highlights, and more details regarding the Federal Communications Commission and U.S. 1455 proposes a law: Prohibiting qualified physicians from engaging in certain advertising for their practices relating to marijuana for medical use [p.1,

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Before 2016, Australian law considered cannabis an illegal drug. A recent study by Lintzeris et al.

Research and Development 52

Research and Development Medicine Access Media 52